Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $1,351,600.00 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Monday, June 1st. The shares were sold at an average price of $67.58, for a total value of $1,351,600.00. Following the transaction, the chief executive officer owned 767,780 shares in the company, valued at $51,886,572.40. This trade represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Torley also recently made the following trade(s):

• On Wednesday, June 3rd, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $69.07, for a total value of $690,700.00.
• On Wednesday, May 13th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $69.19, for a total value of $691,900.00.
• On Tuesday, May 12th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $71.75, for a total value of $1,435,000.00.
• On Monday, April 6th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $63.50, for a total value of $635,000.00.
• On Thursday, April 2nd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $64.24, for a total value of $1,284,800.00.

Halozyme Therapeutics Price Performance

NASDAQ HALO opened at $71.53 on Friday. The company has a market capitalization of $8.48 billion, a PE ratio of 25.73, a price-to-earnings-growth ratio of 0.30 and a beta of 0.88. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. The business’s fifty day moving average is $66.79 and its 200 day moving average is $68.74. Halozyme Therapeutics, Inc. has a fifty-two week low of $51.06 and a fifty-two week high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.06. The company had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.Halozyme Therapeutics’s quarterly revenue was up 42.2% compared to the same quarter last year. During the same period in the previous year, the business earned $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Sell-side analysts predict that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Measured Wealth Private Client Group LLC boosted its position in shares of Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 124 shares during the period. Larson Financial Group LLC boosted its position in shares of Halozyme Therapeutics by 3,118.2% during the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 343 shares during the period. Clearstead Advisors LLC boosted its position in shares of Halozyme Therapeutics by 107.7% during the third quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 265 shares during the period. Harbour Investments Inc. boosted its position in shares of Halozyme Therapeutics by 152.5% during the fourth quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 372 shares during the period. Finally, Penserra Capital Management LLC purchased a new position in shares of Halozyme Therapeutics during the third quarter valued at approximately $52,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. UBS Group reissued a “buy” rating and set a $90.00 price target on shares of Halozyme Therapeutics in a report on Wednesday. Weiss Ratings raised Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, May 12th. Morgan Stanley decreased their price target on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. TD Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, February 18th. Finally, HC Wainwright raised their price target on Halozyme Therapeutics from $90.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Eight research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Halozyme Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $81.60.

Halozyme Therapeutics News Summary

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Zacks Research raised Halozyme’s earnings estimates across multiple future periods, including FY2026, FY2027, and FY2028, signaling confidence in the company’s longer-term profit growth. Halozyme Therapeutics article
• Positive Sentiment: Analysts also increased estimates for several individual quarters in 2027, reinforcing a constructive earnings outlook for Halozyme Therapeutics. Halozyme Therapeutics article
• Neutral Sentiment: One near-term forecast was trimmed slightly and another was revised lower, but the overall analyst tone remains mostly favorable. Halozyme Therapeutics article
• Neutral Sentiment: Recent insider selling by the CEO was disclosed, but the trades were executed under a pre-arranged trading plan, which typically lessens investor concern. Halozyme Therapeutics article

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.